| ISIN | AT0000A1FNT0 |
|---|---|
| Valor Number | 28871817 |
| Bloomberg Global ID | |
| Fund Name | DSC Equity Fund – Healthcare A|A |
| Fund Provider |
Dreyfus Söhne & Cie AG, Banquiers
Aeschenvorstadt 16 | Postfach 4051 Basel Schweiz Phone: +41 61 286 66 66 Web: https://www.dreyfusbank.ch |
| Fund Provider | Dreyfus Söhne & Cie AG, Banquiers |
| Representative in Switzerland |
Dreyfus Söhne & Cie AG, Banquiers Basel |
| Distributor(s) |
Dreyfus Söhne & Cie AG, Banquiers Basel |
| Asset Class | Equities |
| EFC Category | |
| Distribution Policy | Distribution |
| Home Country | Austria |
| Issuing Condition | The fund does not charge any issuing commission and/or fees (units are issued at the NAV) |
| Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
| Investment Strategy *** | N/A |
| Peculiarities |
| Current Price * | 203.26 CHF | 03.11.2025 |
|---|---|---|
| Previous Price * | 203.22 CHF | 31.10.2025 |
| 52 Week High * | 237.48 CHF | 04.03.2025 |
| 52 Week Low * | 186.68 CHF | 08.08.2025 |
| NAV * | 203.26 CHF | 03.11.2025 |
| Issue Price * | 209.36 CHF | 03.11.2025 |
| Redemption Price * | 203.26 CHF | 03.11.2025 |
| Closing Price * | ||
| Indicative Minimum Price | ||
| Fund Assets *** | 38,219,823 | |
| Unit/Share Assets *** | 36,600,033 | |
| Trading Information SIX | ||
| YTD Performance | -9.21% |
30.12.2024 - 03.11.2025
30.12.2024 03.11.2025 |
|---|---|---|
| 1 month | -0.16% |
03.10.2025 - 03.11.2025
03.10.2025 03.11.2025 |
| 3 months | +8.03% |
04.08.2025 - 03.11.2025
04.08.2025 03.11.2025 |
| 6 months | -1.44% |
05.05.2025 - 03.11.2025
05.05.2025 03.11.2025 |
| 1 year | -12.80% |
04.11.2024 - 03.11.2025
04.11.2024 03.11.2025 |
| 2 years | -2.07% |
03.11.2023 - 03.11.2025
03.11.2023 03.11.2025 |
| 3 years | -13.07% |
03.11.2022 - 03.11.2025
03.11.2022 03.11.2025 |
| 5 years | -0.01% |
03.11.2020 - 03.11.2025
03.11.2020 03.11.2025 |
| Equity Participation Rate in % | 96.46 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Real Estate Rate in % | 0.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI Date | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| iShares MSCI Wld HlthCrSect AdvcdETF$Inc | 9.64% | |
|---|---|---|
| Johnson & Johnson | 7.25% | |
| Eli Lilly and Co | 6.31% | |
| Abbott Laboratories | 4.61% | |
| AbbVie Inc | 4.57% | |
| UnitedHealth Group Inc | 3.97% | |
| Merck & Co Inc | 3.30% | |
| AstraZeneca PLC | 3.21% | |
| Novartis AG Registered Shares | 2.77% | |
| Sanofi SA | 2.69% | |
| Last data update | 30.09.2025 | |
| TER | 1.49% |
|---|---|
| TER date | 30.04.2025 |
| Performance Fee *** | |
| PTR | |
| Max. Management Fee *** | 1.50% |
| Ongoing Charges *** | 1.49% |
|
SRRI ***
|
|
| SRRI date *** | 31.10.2025 |